UPC2A is required for high-level azole antifungal resistance in Candida glabrata

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4543-4554

  Whaley, Sarah G ^a,b   Caudle, Kelly E ^a,b,d   Vermitsky, John Paul ^c   Chadwick, Sean G ^c   Toner, Geoffrey ^c   Barker, Katherine S ^a,b   Gygax, Scott E ^c   Rogersa, P David ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

^c LLC   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450; ECM22 PROTEIN, S CEREVISIAE; ERG11 PROTEIN, S CEREVISIAE; ERGOSTEROL; FLUCONAZOLE; ISOPROTEIN; PYRROLE DERIVATIVE; SACCHAROMYCES CEREVISIAE PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; UPC2 PROTEIN, S CEREVISIAE;

ANTIFUNGAL RESISTANCE; BIOSYNTHESIS; CANDIDA ALBICANS; CANDIDA GLABRATA; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; SACCHAROMYCES CEREVISIAE; SEQUENCE HOMOLOGY;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDA GLABRATA; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; FLUCONAZOLE; GENE EXPRESSION REGULATION, FUNGAL; MICROBIAL SENSITIVITY TESTS; PROTEIN ISOFORMS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84905401645     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02217-13     Document Type: Article

References (66)

1. Odds FC. 1988. Candida and candidosis: a review and bibliography, 2nd ed. Bailliere Tindall, London, United Kingdom.
2. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. 2003. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154. http://dx.doi.org/10. 1128/AAC.47.10.3149-3154.2003.
3. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. 1999. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33:217-222. http://dx.doi.org/10.1016/S0732-8893(98) 00160-6.
4. Bader MS, Lai SM, Kumar V, Hinthorn D. 2004. Candidemia in patients with diabetes mellitus: epidemiology and predictors of mortality. Scand. J. Infect. Dis. 36:860-864. http://dx.doi.org/10.1080/00365540410021126.
5. Dan M, Segal R, Marder V, Leibovitz A. 2006. Candida colonization of the vagina in elderly residents of a long-term-care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 25:394-396. http://dx.doi.org/10.1007/s10096-006-0150-y.
6. Goswami D, Goswami R, Banerjee U, Dadhwal V, Miglani S, Lattif AA, Kochupillai N. 2006. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J. Infect. 52:111-117. http://dx.doi.org/10.1016/j. jinf.2005.03.005.
7. Vermitsky JP, Self MJ, Chadwick SG, Trama JP, Adelson ME, Mordechai E, Gygax SE. 2008. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J. Clin. Microbiol. 46:1501-1503. http://dx.doi.org/10.1128/JCM.02485-07.
8. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ, Mycoses Study Group. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54:1110-1122. http://dx.doi.org/10.1093/cid/cis021.
9. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A, Barcelona Candidemia Project Study Group. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835. http://dx.doi.org/ 10.1128/JCM.43.4.1829-1835.2005.
10. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177. http://dx.doi.org/10.1086/378745.
11. Gygax SE, Vermitsky JP, Chadwick SG, Self MJ, Zimmerman JA, Mordechai E, Adelson ME, Trama JP. 2008. Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay. Antimicrob. Agents Chemother. 52:3424-3426. http://dx.doi.org/10.1128/AAC.00462-08.
12. Magill SS, Shields C, Sears CL, Choti M, Merz WG. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535. http://dx.doi.org/10.1128/JCM.44.2.529-535.2006.
13. Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, EngTPatterson TF, Lopez-Ribot J. 2003. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 41:619-622. http://dx.doi.org/10.1128/JCM.41.2.619-622.2003.
14. Vermitsky JP, Edlind TD. 2004. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob. Agents Chemother. 48:3773-3781. http://dx.doi.org/10.1128/AAC.48.10.3773-3781.2004.
15. Davies BS, Wang HS, Rine J. 2005. Dual activators of the sterol biosynthetic pathway of Saccharomyces cerevisiae: similar activation/regulatory domains but different response mechanisms. Mol. Cell. Biol. 25:7375-7385. http://dx.doi.org/10.1128/MCB.25.16.7375-7385.2005.
16. Song JL, Harry JB, Eastman RT, Oliver BG, White TC. 2004. The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrob. Agents Chemother. 48:1136-1144. http://dx.doi.org/10.1128/AAC.48.4.1136-1144.2004.
17. White TC, Silver PM. 2005. Regulation of sterol metabolism in Candida albicans by the UPC2 gene. Biochem. Soc. Trans. 33:1215-1218. http://dx.doi.org/10.1042/BST20051215.
18. Akache B, Wu K, Turcotte B. 2001. Phenotypic analysis of genes encoding yeast zinc cluster proteins. Nucleic Acids Res. 29:2181-2190. http://dx.doi.org/10.1093/nar/29.10.2181.
19. Caudle KE, Barker KS, Wiederhold NP, Xu L, Homayouni R, Rogers PD. 2011. Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot. Cell 10:373-383. http://dx.doi.org/10.1128/EC.00073-10.
20. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhauser J, Rogers PD. 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot. Cell 7:1180-1190. http://dx.doi.org/10.1128/EC.00103-08.
21. Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhauser J. 2010. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob. Agents Chemother. 54:353-359. http://dx.doi.org/10.1128/AAC.01102- 09.
22. Hoehamer CF, Cummings ED, Hilliard GM, Morschhauser J, Rogers PD. 2009. Upc2p-associated differential protein expression in Candida albicans. Proteomics 9:4726-4730. http://dx.doi.org/10.1002/pmic.200900176.
23. Hoot SJ, Smith AR, Brown RP, White TC. 2011. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 55:940-942. http://dx.doi.org/10.1128/AAC.00995-10.
24. Nagi M, Nakayama H, Tanabe K, Bard M, Aoyama T, Okano M, Higashi S, Ueno K, Chibana H, Niimi M, Yamagoe S, Umeyama T, Kajiwara S, Ohno H, Miyazaki Y. 2011. Transcription factors CgUPC2A and CgUPC2B regulate ergosterol biosynthetic genes in Candida glabrata. Genes Cells 16:80-89. http://dx.doi.org/10.1111/j. 1365-2443.2010.01470.x.
25. White TC, Marr KA, Bowden RA. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
26. Shianna KV, Dotson WD, Tove S, Parks LW. 2001. Identification of a UPC2 homolog in Saccharomyces cerevisiae and its involvement in aerobic sterol uptake. J. Bacteriol. 183:830-834. http://dx.doi.org/10.1128/JB.183.3.830-834. 2001.
27. Vik A, Rine J. 2001. Upc2p and Ecm22p, dual regulators of sterol biosynthesis in Saccharomyces cerevisiae. Mol. Cell. Biol. 21:6395-6405. http://dx.doi.org/10.1128/MCB.21.19.6395-6405.2001.
28. MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother. 49:1745-1752. http://dx.doi.org/10.1128/AAC.49.5.1745-1752.2005.
29. Silver PM, Oliver BG, White TC. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3:1391-1397. http://dx.doi.org/10.1128/EC.3.6.1391-1397.2004.
30. Znaidi S, Weber S, Al-Abdin OZ, Bomme P, Saidane S, Drouin S, Lemieux S, De Deken X, Robert F, Raymond M. 2008. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot. Cell 7:836-847. http://dx.doi.org/10.1128/EC.00070-08.
31. Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ, Bennett JE. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39:2708-2717. http://dx.doi.org/ 10.1128/AAC.39.12.2708.
32. Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. 2012. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob. Agents Chemother. 56:4223-4232. http://dx.doi.org/10.1128/AAC.06253-11.
33. Reuss O, Vik A, Kolter R, Morschhauser J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127. http://dx.doi.org/10.1016/j.gene.2004.06.021.
34. Amberg DC, Burke DJ, Strathern JN. 2006. Isolation of yeast genomic DNA for Southern blot analysis. CSH Protoc. http://dx.doi.org/10.1101/pdb.prot4149.
35. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
36. Epp E, Vanier G, Harcus D, Lee AY, Jansen G, Hallett M, Sheppard DC, Thomas DY, Munro CA, Mullick A, Whiteway M. 2010. Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence. PLoS Pathog. 6:e1000753. http://dx.doi.org/10.1371/journal.ppat.1000753.
37. Onyewu C, Blankenship JR, Del Poeta M, Heitman J. 2003. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47:956-964. http://dx.doi.org/10.1128/AAC.47.3. 956-964.2003.
38. Espinel-Ingroff A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
39. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. 1999. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43:2753-2765.
40. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
41. Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. 1999. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J. Clin. Microbiol. 37:3332-3337.
42. Schmitt ME, Brown TA, Trumpower BL. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18:3091-3092. http://dx.doi.org/10.1093/nar/18.10.3091.
43. Liu TT, Lee RE, Barker KS, Lee RE, Wei L, Homayouni R, Rogers PD. 2005. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 49:2226-2236. http://dx.doi.org/10.1128/AAC.49.6.2226-2236. 2005.
44. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. 2012. The PATH (Prospective Antifungal Therapy) Alliance (R) registry and invasive fungal infections: update 2012. Diagn. Microbiol. Infect. Dis. 73:293-300. http://dx.doi.org/10.1016/j.diagmicrobio.2012.06.012.
45. Hoot SJ, Brown RP, Oliver BG, White TC. 2010. The UPC2 promoter in Candida albicans contains two cis-acting elements that bind directly to Upc2p, resulting in transcriptional autoregulation. Eukaryot. Cell 9:1354-1362. http://dx.doi.org/10.1128/EC.00130-10.
46. Oliver BG, Song JL, Choiniere JH, White TC. 2007. cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p. Eukaryot. Cell 6:2231-2239. http://dx.doi.org/10. 1128/EC.00331-06.
47. Henry KW, Nickels JT, Edlind TD. 2000. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 44:2693-2700. http://dx.doi.org/10.1128/AAC.44.10.2693-2700. 2000.
48. Smith SJ, Crowley JH, Parks LW. 1996. Transcriptional regulation by ergosterol in the yeast Saccharomyces cerevisiae. Mol. Cell. Biol. 16:5427-5432.
49. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.
50. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, Kontoyiannis DP, Raad II. 2002. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112:380-385. http://dx.doi.org/10.1016/S0002-9343(01)01130-5.
51. Ghannoum MA, Rice LB. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12:501-517.
52. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. 1998. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J. Clin. Microbiol. 36:1886-1889.
53. Schuman P, Sobel JD, Ohmit SE, Mayer KH, Carpenter CC, Rompalo A, Duerr A, Smith DK, Warren D, Klein RS. 1998. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin. Infect. Dis. 27:1161-1167.
54. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35:627-630. http://dx.doi.org/10. 1086/342300.
55. Vazquez JA, Sobel JD, Peng G, Steele-Moore L, Schuman P, Holloway W, Neaton JD. 1999. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin. Infect. Dis. 28:1025-1031.
56. Bennett JE, Izumikawa K, Marr KA. 2004. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48:1773-1777. http://dx.doi.org/10.1128/AAC.48.5.1773-1777. 2004.
57. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. 2005. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Microbiol. 43:2155-2162. http://dx.doi.org/10.1128/JCM.43.5.2155-2162.2005.
58. Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, Fadda G, Rohde B, Bauser C, Bader O, Sanglard D. 2009. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5:e1000268. http://dx.doi.org/10.1371/journal. ppat.1000268.
59. Tsai HF, Krol AA, Sarti KE, Bennett JE. 2006. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob. Agents Chemother. 50:1384-1392. http://dx.doi.org/10.1128/AAC.50.4.1384-1392.2006.
60. Vermitsky JP, Earhart KD, Smith WL, Homayouni R, Edlind TD, Rogers PD. 2006. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol. Microbiol. 61:704-722. http://dx.doi.org/10.1111/j.1365-2958.2006.05235.x.
61. Hoot SJ, Oliver BG, White TC. 2008. Candida albicans UPC2 is transcriptionally induced in response to antifungal drugs and anaerobicity through Upc2p-dependent and -independent mechanisms. Microbiology 154:2748-2756. http://dx.doi.org/10.1099/mic.0.2008/017475-0.
62. Barker KS, Pearson MM, Rogers PD. 2003. Identification of genes differentially expressed in association with reduced azole susceptibility in Saccharomyces cerevisiae. J. Antimicrob. Chemother. 51:1131-1140. http://dx.doi.org/10.1093/jac/dkg217.
63. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhauser J, Rogers PD. 2012. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot. Cell 11:1289-1299. http://dx.doi.org/10.1128/EC. 00215-12.
64. Thakur JK, Arthanari H, Yang F, Pan SJ, Fan X, Breger J, Frueh DP, Gulshan K, Li DK, Mylonakis E, Struhl K, Moye-Rowley WS, Cormack BP, Wagner G, Naar AM. 2008. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 452:604-609. http://dx.doi.org/10.1038/nature06836.
65. Krishnamurthy SS, Prasad R. 1999. Membrane fluidity affects functions of Cdr1p, a multidrug ABC transporter of Candida albicans. FEMS Microbiol. Lett. 173:475-481. http://dx.doi.org/10.1016/S0378-1097(99)00237-2.
66. Kohli A, Smriti Mukhopadhyay K, Rattan A, Prasad R. 2002. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob. Agents Chemother. 46:1046-1052. http://dx.doi.org/10.1128/AAC.46.4.1046-1052.2002.